Piramal Life Sciences, Mumbai based drug developer on Wednesday said it had received regulatory approval by Drug Controller General of India to conduct two Phase I/II combination studies for its cancer molecule P276 which would help it develop drugs against pancreatic, head and neck cancer.
The objective of both studies is to identify the right doses of P276 to be used in combination with chemotherapeutic drugs and to evaluate the benefit of the same in pancreatic and head and neck cancer patients, the company said in a note to the stock exchanges.
The stock of the company was up by 4.9 per cent to Rs51.50 a share on Bombay Stock Exchange at 12.00 pm. The company has the upper circuit limit of 5 per cent daily increase on the exchange.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app